资金流向方面，今日该股主力资金净流入8193.13万元，其中，特大单净流入8723.76万元，大单资金净 流出530.63万元。近5日主力资金净流入7863.67万元。（数据宝） 博晖创新今日涨停，全天换手率8.16%，成交额4.58亿元，振幅19.60%。龙虎榜数据显示，机构净卖出 1542.67万元，深股通净卖出29.50万元，营业部席位合计净买入3805.26万元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净卖出1542.67万元，深 股通净卖出29.50万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交1.37亿元，其中，买入成交额为7942.16 万元，卖出成交额为5709.07万元，合计净买入2233.09万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖一，合计净卖出1542.67万元，深股 通为第五大卖出营业部，买入金额为803.71万元，卖出金额为833.21万元，合计净卖出29.50万元。 （原标题：博晖创新龙虎榜数据（11月12日）） 博晖创新11月12日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） ...

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.44% on November 12, with significant gains from specific stocks, while the overall market indices showed a decline [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4000.14, down 0.07% - The Shenzhen Component Index closed at 13240.62, down 0.36% [1] Group 2: Top Gainers in Biopharmaceutical Sector - BGI Innovation (300318) led the gains with a closing price of 7.20, up 20.00% with a trading volume of 651,300 shares and a transaction value of 458 million yuan - Sanyuan Gene (920344) followed with a closing price of 33.15, up 12.45% and a trading volume of 85,300 shares [1] - Other notable gainers include: - Sangfor Biopharma (688336) at 68.50, up 6.60% - Sai Sheng Pharmaceutical (300485) at 12.88, up 4.63% [1] Group 3: Market Capital Flow - The biopharmaceutical sector saw a net inflow of 325 million yuan from institutional investors, while retail investors experienced a net outflow of 317 million yuan [2] - The top stocks by net inflow from institutional investors included: - Sangfor Biopharma (688336) with a net inflow of 136 million yuan - He Yuan Biopharma (688765) with a net inflow of 108 million yuan [3]

Core Insights - The monkeypox concept sector saw a rise of 1.57%, ranking third among concept sectors, with 57 stocks increasing in value, including significant gains from companies like Bo Hui Innovation, which hit a 20% limit up, and others like He Fu China and Zhong Sheng Pharmaceutical reaching their daily limit up as well [1][2] Group 1: Market Performance - The monkeypox concept sector had a net inflow of 5.92 billion yuan, with 35 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top net inflow was from Zhong Sheng Pharmaceutical, which saw a net inflow of 4.36 billion yuan, followed by Fu Xiang Pharmaceutical and Bo Hui Innovation with net inflows of 1.28 billion yuan and 819.31 million yuan respectively [2][3] Group 2: Stock Performance - The stocks with the highest net inflow ratios included Bo Hui Innovation at 17.88%, Zhong Sheng Pharmaceutical at 14.67%, and Dong Fang Biological at 13.11% [3] - Notable stock performances included Bo Hui Innovation with a 20% increase, Zhong Sheng Pharmaceutical with a 10.02% increase, and He Fu China with a 10.02% increase as well [1][7]

Core Viewpoint - The Shanghai Composite Index decreased by 0.21% today, with significant declines in the electric equipment sector, which saw the largest drop of 2.31% [2] Industry Performance Summary - The oil and petrochemical sector led the gains with an increase of 1.27%, followed by the banking sector at 1.10% and the comprehensive sector at 1.01% [2] - The electric equipment sector experienced the largest decline at 2.31%, followed by the defense and military industry at 1.70% and the computer sector at 1.28% [2] - A total of 1513 stocks rose, with 65 hitting the daily limit up, while 3819 stocks fell, including 10 hitting the daily limit down [2] Trading Volume and Value - The total trading volume reached 1,081 million shares, with a total transaction value of 15,923.01 billion yuan, reflecting a decrease of 1.61% compared to the previous trading day [2]

Market Overview - The Shanghai Composite Index increased by 0.27% as of 10:28 AM, with a trading volume of 61.67 billion shares and a transaction value of 893.47 billion yuan, a decrease of 6.50% compared to the previous trading day [1] Industry Performance - The top-performing industries included: - Oil and Petrochemicals: Increased by 1.77% with a transaction value of 8.62 billion yuan, led by Sinopec Oilfield Service, which rose by 10.21% [1] - Banking: Increased by 1.52% with a transaction value of 15.41 billion yuan, led by Agricultural Bank of China, which rose by 2.89% [1] - Home Appliances: Increased by 1.01% with a transaction value of 14.36 billion yuan, led by Beiyikang, which rose by 10.78% [1] - The worst-performing industries included: - Communication: Decreased by 1.33% with a transaction value of 34.89 billion yuan, led by Yongding Co., which fell by 5.45% [2] - Electric Power Equipment: Decreased by 1.25% with a transaction value of 148.46 billion yuan, led by Canadian Solar, which fell by 13.92% [2] - National Defense and Military Industry: Decreased by 0.92% with a transaction value of 16.72 billion yuan, led by Triangle Defense, which fell by 7.34% [2] Stock Performance - A total of 1,864 stocks rose, with 49 hitting the daily limit, while 3,394 stocks fell, with 2 hitting the lower limit [1]

Group 1 - The flu concept is experiencing renewed activity, leading to significant stock movements in related companies [1] - Te Yi Pharmaceutical has achieved two consecutive trading limits, indicating strong market interest [1] - Bo Hui Innovation has reached a 20% daily limit increase, reflecting positive investor sentiment [1] Group 2 - Panlong Pharmaceutical has also hit the daily limit, showcasing its strong performance in the market [1] - Other companies such as Zhongsheng Pharmaceutical, Ha Sanlian, and Jinhua Co. have seen their stocks rise in response to the flu concept's resurgence [1]

智通财经APP讯，博晖创新(300318.SZ)发布公告，近日，公司控股孙公司博晖生物制药股份有限公司 (以下简称"廊坊博晖")与北京百晖生物科技有限公司(以下简称"百晖生物")联合申报的冻干b型流感嗜血 杆菌结合疫苗，获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临床试验。 据悉，廊坊博晖与百晖生物联合申报的冻干b型流感嗜血杆菌结合疫苗，通过纯化的Hib荚膜多糖抗原与 破伤风类毒素结合生成的多糖蛋白结合物刺激机体产生免疫反应，用于预防由b型流感嗜血杆菌引起的 侵袭性感染(脑膜炎、肺炎、败血症、蜂窝组织炎、关节炎、会厌炎等)。目前国内已上市的冻干Hib结 合疫苗厂家包括北京民海生物科技有限公司。 ...

Core Viewpoint - The company BoHui Innovation (300318.SZ) announced that its subsidiary BoHui Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of a lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine [1] Group 1 - The lyophilized Hib conjugate vaccine is developed in collaboration with Beijing Baihui Biotechnology Co., Ltd. [1] - The vaccine aims to stimulate immune response through a purified Hib capsular polysaccharide antigen combined with tetanus toxoid, targeting invasive infections caused by Hib, such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1]

药物名称：冻干 b 型流感嗜血杆菌结合疫苗； 证券代码：300318 证券简称：博晖创新 公告编号：临 2025-036 北京博晖创新生物技术集团股份有限公司 关于控股孙公司联合获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京博晖创新生物技术集团股份有限公司（以下简称"公司"）控股 孙公司博晖生物制药股份有限公司（以下简称"廊坊博晖"）与北京百晖生物科 技有限公司（以下简称"百晖生物"）联合申报的冻干 b 型流感嗜血杆菌结合疫 苗，获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临 床试验。具体情况如下： 一、基本情况 受理号：CXSL2500616； 通知书编号：2025LP02755； 药品类型：预防用生物制品； 注册分类：3.3； 申请人：博晖生物制药股份有限公司、北京百晖生物科技有限公司； 适应症：本疫苗接种后，可使机体产生体液免疫应答。用于预防由 b 型流感 嗜血杆菌引起的侵袭性感染（包括脑膜炎、肺炎、败血症、蜂窝组织炎、关节炎、 会厌炎等）。 二、其他相关情况 廊坊博晖与百晖生物联合申报的 ...

Core Viewpoint - The company announced that its subsidiary, Bohui Biopharmaceutical Co., Ltd., in collaboration with Beijing Baihui Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of a lyophilized type B Haemophilus influenzae conjugate vaccine [1] Group 1 - The clinical trial approval indicates progress in the development of the vaccine, which may enhance the company's product portfolio in the biopharmaceutical sector [1] - The collaboration with Beijing Baihui Biotechnology Co., Ltd. suggests a strategic partnership aimed at leveraging combined expertise for vaccine development [1]